152 related articles for article (PubMed ID: 37536209)
1. Neutral sphingomyelinase 2 inhibitors based on the pyrazolo[1,5-a]pyrimidin-3-amine scaffold.
Novotna K; Thomas AG; Stepanek O; Murphy B; Hin N; Skacel J; Mueller L; Tenora L; Pal A; Alt J; Wu Y; Paule J; Rais R; Slusher BS; Tsukamoto T
Eur J Med Chem; 2023 Nov; 259():115674. PubMed ID: 37536209
[TBL] [Abstract][Full Text] [Related]
2. Inhibition of neutral sphingomyelinase 2 reduces extracellular vesicle release from neurons, oligodendrocytes, and activated microglial cells following acute brain injury.
Tallon C; Picciolini S; Yoo SW; Thomas AG; Pal A; Alt J; Carlomagno C; Gualerzi A; Rais R; Haughey NJ; Bedoni M; Slusher BS
Biochem Pharmacol; 2021 Dec; 194():114796. PubMed ID: 34678224
[TBL] [Abstract][Full Text] [Related]
3. Inhibition of neutral sphingomyelinase 2 impairs HIV-1 envelope formation and substantially delays or eliminates viral rebound.
Yoo SW; Waheed AA; Deme P; Tohumeken S; Rais R; Smith MD; DeMarino C; Calabresi PA; Kashanchi F; Freed EO; Slusher BS; Haughey NJ
Proc Natl Acad Sci U S A; 2023 Jul; 120(28):e2219543120. PubMed ID: 37406092
[TBL] [Abstract][Full Text] [Related]
4. Neutral sphingomyelinase 2 inhibition attenuates extracellular vesicle release and improves neurobehavioral deficits in murine HIV.
Zhu X; Hollinger KR; Huang Y; Borjabad A; Kim BH; Arab T; Thomas AG; Moniruzzaman M; Lovell L; Turchinovich A; Witwer KW; Volsky DJ; Haughey NJ; Slusher BS
Neurobiol Dis; 2022 Jul; 169():105734. PubMed ID: 35462006
[TBL] [Abstract][Full Text] [Related]
5. A novel and potent brain penetrant inhibitor of extracellular vesicle release.
Rojas C; Sala M; Thomas AG; Datta Chaudhuri A; Yoo SW; Li Z; Dash RP; Rais R; Haughey NJ; Nencka R; Slusher B
Br J Pharmacol; 2019 Oct; 176(19):3857-3870. PubMed ID: 31273753
[TBL] [Abstract][Full Text] [Related]
6. Novel Human Neutral Sphingomyelinase 2 Inhibitors as Potential Therapeutics for Alzheimer's Disease.
Šála M; Hollinger KR; Thomas AG; Dash RP; Tallon C; Veeravalli V; Lovell L; Kögler M; Hřebabecký H; Procházková E; Nešuta O; Donoghue A; Lam J; Rais R; Rojas C; Slusher BS; Nencka R
J Med Chem; 2020 Jun; 63(11):6028-6056. PubMed ID: 32298582
[TBL] [Abstract][Full Text] [Related]
7. Neutral sphingomyelinase 2 inhibitors based on the 4-(1H-imidazol-2-yl)-2,6-dialkoxyphenol scaffold.
Stepanek O; Hin N; Thomas AG; Dash RP; Alt J; Rais R; Rojas C; Slusher BS; Tsukamoto T
Eur J Med Chem; 2019 May; 170():276-289. PubMed ID: 30921693
[TBL] [Abstract][Full Text] [Related]
8. Inhibiting tau-induced elevated nSMase2 activity and ceramides is therapeutic in murine Alzheimer's disease.
Tallon C; Bell BJ; Malvankar MM; Deme P; Nogueras-Ortiz C; Eren E; Thomas AG; Hollinger KR; Pal A; Mustapic M; Huang M; Coleman K; Joe TR; Rais R; Haughey NJ; Kapogiannis D; Slusher BS
Res Sq; 2023 Jul; ():. PubMed ID: 37502930
[TBL] [Abstract][Full Text] [Related]
9. Inhibiting tau-induced elevated nSMase2 activity and ceramides is therapeutic in an Alzheimer's disease mouse model.
Tallon C; Bell BJ; Malvankar MM; Deme P; Nogueras-Ortiz C; Eren E; Thomas AG; Hollinger KR; Pal A; Mustapic M; Huang M; Coleman K; Joe TR; Rais R; Haughey NJ; Kapogiannis D; Slusher BS
Transl Neurodegener; 2023 Dec; 12(1):56. PubMed ID: 38049923
[TBL] [Abstract][Full Text] [Related]
10. Cambinol, a novel inhibitor of neutral sphingomyelinase 2 shows neuroprotective properties.
Figuera-Losada M; Stathis M; Dorskind JM; Thomas AG; Bandaru VV; Yoo SW; Westwood NJ; Rogers GW; McArthur JC; Haughey NJ; Slusher BS; Rojas C
PLoS One; 2015; 10(5):e0124481. PubMed ID: 26010541
[TBL] [Abstract][Full Text] [Related]
11. Neuronal deletion of nSMase2 reduces the production of Aβ and directly protects neurons.
Tohumeken S; Deme P; Yoo SW; Gupta S; Rais R; Slusher BS; Haughey NJ
Neurobiol Dis; 2023 Feb; 177():105987. PubMed ID: 36603748
[TBL] [Abstract][Full Text] [Related]
12. Interaction of Synaptosomal-Associated Protein 25 with Neutral Sphingomyelinase 2: Functional Impact on the Sphingomyelin Pathway.
Won JH; Jeon HJ; Kim SK; Shin IC; Jang JM; Ha HC; Back MJ; Kim DK
Neuroscience; 2020 Feb; 427():1-15. PubMed ID: 31765623
[TBL] [Abstract][Full Text] [Related]
13. 7 H-Pyrrolo[2,3- d]pyrimidin-4-amine-Based Inhibitors of Calcium-Dependent Protein Kinase 1 Have Distinct Inhibitory and Oral Pharmacokinetic Characteristics Compared with 1 H-Pyrazolo[3,4- d]pyrimidin-4-amine-Based Inhibitors.
Vidadala RSR; Golkowski M; Hulverson MA; Choi R; McCloskey MC; Whitman GR; Huang W; Arnold SLM; Barrett LK; Fan E; Merritt EA; Van Voorhis WC; Ojo KK; Maly DJ
ACS Infect Dis; 2018 Apr; 4(4):516-522. PubMed ID: 29522315
[TBL] [Abstract][Full Text] [Related]
14. Identification and evaluation of neutral sphingomyelinase 2 inhibitors.
Lee DH; Kim SH; Ahn KH; Kim SK; Choi JM; Ji JE; Won JH; Park YH; Lim C; Kim S; Kim DK
Arch Pharm Res; 2011 Feb; 34(2):229-36. PubMed ID: 21380806
[TBL] [Abstract][Full Text] [Related]
15. Synthesis and biological evaluation of some novel pyrazolopyrimidines incorporating a benzothiazole ring system.
Azam MA; Dharanya L; Mehta CC; Sachdeva S
Acta Pharm; 2013 Mar; 63(1):19-30. PubMed ID: 23482310
[TBL] [Abstract][Full Text] [Related]
16. Regulated translocation of neutral sphingomyelinase-2 to the plasma membrane drives insulin resistance in steatotic hepatocytes.
El-Amouri S; Karakashian A; Bieberich E; Nikolova-Karakashian M
J Lipid Res; 2023 Oct; 64(10):100435. PubMed ID: 37640282
[TBL] [Abstract][Full Text] [Related]
17. Neutral sphingomyelinase-2 and cardiometabolic diseases.
Sindhu S; Leung YH; Arefanian H; Madiraju SRM; Al-Mulla F; Ahmad R; Prentki M
Obes Rev; 2021 Aug; 22(8):e13248. PubMed ID: 33738905
[TBL] [Abstract][Full Text] [Related]
18. Role for mammalian neutral sphingomyelinase 2 in confluence-induced growth arrest of MCF7 cells.
Marchesini N; Osta W; Bielawski J; Luberto C; Obeid LM; Hannun YA
J Biol Chem; 2004 Jun; 279(24):25101-11. PubMed ID: 15051724
[TBL] [Abstract][Full Text] [Related]
19. Synthesis and SAR of 3-arylsulfonyl-pyrazolo[1,5-a]pyrimidines as potent serotonin 5-HT6 receptor antagonists.
Ivachtchenko AV; Golovina ES; Kadieva MG; Kysil VM; Mitkin OD; Tkachenko SE; Okun I
Bioorg Med Chem; 2011 Feb; 19(4):1482-91. PubMed ID: 21277782
[TBL] [Abstract][Full Text] [Related]
20. A signaling cascade mediated by ceramide, src and PDGFRβ coordinates the activation of the redox-sensitive neutral sphingomyelinase-2 and sphingosine kinase-1.
Cinq-Frais C; Coatrieux C; Grazide MH; Hannun YA; Nègre-Salvayre A; Salvayre R; Augé N
Biochim Biophys Acta; 2013 Aug; 1831(8):1344-56. PubMed ID: 23651497
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
